Adalimumab biosimilar - Laboratorios Richmond
Latest Information Update: 15 Mar 2024
At a glance
- Originator Laboratorios Richmond
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis
Most Recent Events
- 20 Oct 2023 Laboratorios Richmond completes a phase-I trial (In volunteers) in Argentina (SC) (NCT06291948)